These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34137664)

  • 1. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update.
    D'Urzo AD; Singh D; Donohue JF; Chapman KR; Wise RA
    Expert Rev Respir Med; 2021 Sep; 15(9):1093-1106. PubMed ID: 34137664
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
    Haley R; Gupta N; Sethi S
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.
    Rebordosa C; Plana E; Rubino A; Aguado J; Martinez D; Lei A; Daoud S; Saigi-Morgui N; Perez-Gutthann S; Rivero-Ferrer E
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1715-1733. PubMed ID: 35941901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.
    D'Urzo AD; Singh D; Donohue JF; Chapman KR
    Ther Adv Respir Dis; 2019; 13():1753466619850725. PubMed ID: 31096854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
    Bateman ED; Chapman KR; Singh D; D'Urzo AD; Molins E; Leselbaum A; Gil EG
    Respir Res; 2015 Aug; 16(1):92. PubMed ID: 26233481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
    Heo YA
    Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
    Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
    Babu KS; Morjaria JB
    Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease.
    D'Urzo T; Donohue JF; Price D; Miravitlles M; Kerwin E
    Expert Rev Respir Med; 2015 Oct; 9(5):519-32. PubMed ID: 26366803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
    Plate T; Friedrich FW; Beier J
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1335-1347. PubMed ID: 32606643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
    Blasi F; Canonica GW; Miravitlles M
    Respir Res; 2017 Jan; 18(1):19. PubMed ID: 28100244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
    Donohue JF; Soong W; Wu X; Shrestha P; Lei A
    Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
    Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.
    Singh D; D'Urzo AD; Donohue JF; Kerwin EM; Molins E; Chuecos F; Ribera A; Jarreta D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2835-2848. PubMed ID: 31827323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.
    Sun Y; Molins E; Daoud SZ; Trivedi R; Stewart C; Lamarca R; Bharali P; Garcia-Gil E
    Respir Med; 2023 Nov; 218():107393. PubMed ID: 37640273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.